Research Author

Xavier M. Anguela

Spark Therapeutics (United States)

ORCID OpenAlex profile

0Studies tracked

0Claims cite

0Videos use

Average study score: 52/100

Bibliography

Studies by this author

1 study attributed to Xavier M. Anguela on the platform. Click a card to read the full analysis.

Study

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

To evaluate the safety and preliminary efficacy of a single infusion of AAV gene therapy vector SPK-8011 in men with severe hemophilia A, focusing on the durability of factor VIII expression and reduction in bleeding.

Moderate

Lindsey A. George,Paul Edward Monahan,M. Elaine Eyster+16 more

Read analysis